Finance
Wrapping up a surprisingly solid earnings season
June 4, 2025
Netflix might still wear the crown with over 300 million subscribers, but who’s the surprising No. 2 in streaming? It’s not Amazon Prime, Disney+, or Max. Just four months after its debut, India’s JioHotstar surged into second place — and it has one sport to thank for the meteoric rise.
Wall Street had a sleepy start Monday before jolting awake late in the trading day. Reports surfaced that the White House is pressuring chip software firms to cut off sales to Chinese customers. That spooked markets: the S&P 500 dipped 0.6%, the Nasdaq 100 slipped 0.5%, and the small-cap Russell 2000 dropped 1.1%. Real estate was the lone S&P sector not in the red. Energy and materials dragged the hardest.
Nvidia, the reigning champ of the AI semiconductor space, served up an earnings surprise yesterday that kept bullish investors grooving. Even with tightened export rules, Nvidia’s core business — and the AI trade more broadly — remains very much alive.
The company posted adjusted EPS of $0.96, a figure that factors in a hefty $4.5 billion impairment related to the U.S. export clampdown.
Bottom line: sales stayed strong, but profits took a short-term hit due to lost revenue from China-bound chips (H20 series, specifically).
Per Bloomberg Intelligence: “Nvidia’s forecast of $45 billion for Q2 is just $3 billion shy of pre-ban analyst consensus — despite an $8 billion hole from potential China sales.” The takeaway? Nvidia’s finding new buyers faster than policymakers can close doors.
And the real surprise? The earnings beat didn’t come from AI chips — it came from gaming. Data center sales narrowly missed estimates by $100 million, while gaming GPU revenue crushed forecasts, hitting $3.8 billion versus an expected $2.8 billion.
So, what’s next? Nvidia’s guidance for the current quarter includes $45B in revenue (give or take 2%) and a lofty 72% gross margin. Revenue came in a tad light, but margins were slightly better than Wall Street was expecting.
Presented by Turn Therapeutics
When faced with a deadly infection boasting a 70% fatality rate and no existing cure, Bradley Burnam did what most wouldn’t dare—he created the solution himself. Enter Hexagen: a groundbreaking formula that Burnam personally shepherded through the FDA clearance process for just $24,000. But he didn’t stop there. Building on this success, Burnam expanded the technology, secured two additional FDA clearances, and founded a company that’s rewriting the rules on self-made medical innovation: Turn Therapeutics.
Hexagen isn’t just breaking barriers; it’s healing them. Cleared for acute wound care and atopic dermatitis, this powerhouse formula is now on the brink of a bigger leap. Turn, the company behind Hexagen, is paving the way to expand its applications, proving there’s much more to its potential than meets the eye.
Turn just locked in a game-changing commitment—up to $75M in investment from GEM Global Yield Fund. This private equity boost is tied to the company’s plans to go public, setting the stage for Turn to make bold moves in the market spotlight..2
Turn is rolling out institutional, accredited, and unaccredited investors to participate in their current crowdfunding campaign — but only until January 2025.3
Think Amazon’s all about electronics and paper towels? Think again. The retail juggernaut is now the largest apparel seller in the country — and it’s not even close.
Even Jeff Bezos made headlines with his questionable Coachella outfit in 2023, featuring a $12 butterfly shirt from Amazon. But it turns out average shoppers love Amazon fashion basics. Just two examples — camisoles and underwear — together boast nearly 200K reviews and an average rating of 4.4 stars.
Last year, Amazon more than doubled both the unit sales and revenue of its closest competitor, Walmart, in apparel.
So what gives? Part of it comes down to our definition of “fashion.” As one analyst said, “Most of what people wear day-to-day isn’t haute couture — it’s simple, practical, affordable. That’s Amazon’s sweet spot.”
The pandemic also accelerated e-commerce shopping habits, especially among younger consumers who prefer scrolling over strolling.
Presented by Atombeam
Big tech, small data… Why are industry leaders like NVIDIA, Intel and Ericsson partnering with Atombeam?1 It’s the company reimagining machine communication — and potentially the future of big tech. That’s thanks to Neurpac, Atombeam’s patented software technology that can reduce the size of low-entropy data by an average of 75%.
Lightning fast… Neurpac enables 2-4x more data to be sent faster and more securely over existing networks—no hardware upgrades — just smart, AI-powered software.
To the moon and back… The U.S Space Force and U.S. Air Force have already been on Atombeam’s customer books — and the company’s potential market is still gaining ground. Atombeam is in discussions with multiple companies, ranging from a major packaging brand to an EV enterprise.
$16M has already been invested into the company. You can invest before the round closes in 29 days.2
1 The partnership relationship varies between companies and can include the following: inclusion on a preferred vendor list, invitations to participate in certain forums; listed on the other company's website, and introduction and networking opportunities.
Advertiser's disclosures:
¹ The Company's Formula (Gx-03/Hexagen/Atopx) Has Received 510k Marketing Approval As A Medical Device Indicated For The Management Of Symptoms Related To Atopic Dermatitis/Eczema. The Formula Has Not Received Approval As A Drug For The Treatment Of Eczema Or Onychomycosis.
² A plan to IPO is no guarantee that an actual IPO will occur.
³ Please read the offering circular and related risks at StartEngine’s Turn Therapeutics webpage. This is a paid advertisement for Turn Therapeutics Regulation CF Offering. This Reg CF offering is made available through StartEngine Primary, LLC, member FINRA/SIPC.
Investing in private company securities is not suitable for all investors because it is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities.
